Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
RG6292 (vopikitug) targets CD25 (IL-2Rα) and mediates regulatory T-cell depletion while not interfering with IL-2 signaling. Peripheral and intratumoral Treg depletion was shown in two phase I studies. However, RG6292 alone or in combination with atezolizumab was insufficient to reverse and rescue from established resistance mechanisms in solid tumors.
Authors
- Gabriel Schnetzler (ORCID: https://orcid.org/0000-0003-4889-8596)
- Daniel J. Renouf (ORCID: https://orcid.org/0000-0002-7597-6089)
- Enrique Gómez Alcaide (ORCID: https://orcid.org/0000-0003-0542-303X)
- Aung Naing (ORCID: https://orcid.org/0000-0002-4803-8513)
- Vaios Karanikas (ORCID: https://orcid.org/0009-0009-9523-7425)
- Tamara Tanos (ORCID: https://orcid.org/0000-0002-3217-3104)
- Miguel F. Sanmamed (ORCID: https://orcid.org/0000-0002-7295-6074)
- Linxinyu Xu
- Bernard Doger de Spéville (ORCID: https://orcid.org/0009-0004-3264-5433)
- Nicole Justies
- Vladimir Galvao (ORCID: https://orcid.org/0009-0007-8139-8215)
- Michael Ong (ORCID: https://orcid.org/0000-0002-0347-5541)
- Kristoffer Staal Rohrberg (ORCID: https://orcid.org/0000-0002-5448-9003)
- Valentina Gambardella (ORCID: https://orcid.org/0000-0001-6081-8830)
- Stephen J. Luen (ORCID: https://orcid.org/0000-0001-6962-2906)
- Samira Curdt
- Emiliano Calvo (ORCID: https://orcid.org/0000-0003-4921-829X)
- Maria Amann (ORCID: https://orcid.org/0009-0006-0104-0057)
- Nicolas Städler (ORCID: https://orcid.org/0000-0001-8212-7459)
- Christophe Boetsch (ORCID: https://orcid.org/0009-0005-8467-0339)
- María E. Rodríguez-Ruiz (ORCID: https://orcid.org/0000-0002-9765-2499)
- Jean‐Pascal Machiels (ORCID: https://orcid.org/0000-0001-6369-9742)
- Rachel Galot (ORCID: https://orcid.org/0000-0002-0596-4752)
- Eva Rossmann (ORCID: https://orcid.org/0000-0002-3557-6013)
- Anna Spreafico (ORCID: https://orcid.org/0000-0002-3034-3042)
- T Kolben (ORCID: https://orcid.org/0000-0001-6376-3732)
- Yuying Xie (ORCID: https://orcid.org/0000-0002-5278-8675)
- Kevin Smart
Institutions
- Roche (Switzerland) (CH)
- University of Copenhagen (DK)
- BC Cancer Agency (CA)
- Cliniques Universitaires Saint-Luc (BE)
- University Health Network (CA)
- The University of Texas MD Anderson Cancer Center (US)
- Peter MacCallum Cancer Centre (AU)
- Ottawa Hospital (CA)
- Copenhagen University Hospital (DK)
- Princess Margaret Cancer Centre (CA)
- Rigshospitalet (DK)
- Roche (Canada) (CA)
- Roche Pharma AG (Germany) (DE)
- Hospital Clínico Universitario de Valencia (ES)
- Centro Oncológico de Galicia (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Navarre Institute of Health Research (ES)
- Roche (United Kingdom) (GB)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Clinica Universidad de Navarra (ES)
- Vall d'Hebron Institute of Oncology (ES)
- IT University of Copenhagen (DK)
- Universidad de Navarra (ES)
- UCLouvain (BE)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0638
- Citations
- 11
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 11.50
Funders
- Pfizer
- AstraZeneca
- BeiGene
- Symphogen
- Genentech